F2G has raised €53M to advance its news class of treatments for life-threatening fungal infections, including invasive aspergillosis. The technology has attracted some of the major biotech investors in Europe.
Based in Manchester (UK), F2G focuses on developing therapies for invasive fungal infections such as aspergillosis.
This type of infections mostly affect patients that are immuno-compromised. As more and more people undergo treatments for cancer, organ transplants and take other aggressive medication that affects the immune system, there’s a big need for antifungals (as well as some innovative diagnosis).
The problem is that there isn’t much choice when it comes to these therapies. Most of the infections with Candida and Aspergillus are treated with azoles (a class of antifungals). However, resistance to azoles is rapidly increasing, a big problem in infectious diseases.
F2G has discovered a new class of antifungals (orotomides). This class is effective against pathogenic moulds, including resistant ones due to its novel mechanism of action.